Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 1.00 |
| ▸ | FNTB | P49356 | 18/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 17/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225637 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL30144590 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL4738546 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL8495867 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL14169166 | 0.93 | FNTA (0.87) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL9058589 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL16136645 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL29642927 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL1802360 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| Hydrochloric Acid SCHEMBL8496569 | 0.91 | FNTA (0.98) | FNTAFNTBPGGT1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2014160729-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS RESEARCH INDIA PVT. LTD (IN) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | FNTA 1114/4885FNTB 1259/4885PGGT1B 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.